Patents Examined by Stacy B. Chen
-
Patent number: 11667931Abstract: The present invention relates to the production of adeno-associated viral vectors in insect cells. The insect cells therefore comprise a first nucleotide sequence encoding the adeno-associated virus (AAV) capsid proteins, whereby the initiation codon for translation of the AAV VP1 capsid protein is an AUG. Upstream of the VP1 open reading frame an alternative out of frame start codon is placed such that translation initiation of the VP1 protein is modified, i.e. reduced, to allow production of VP1:VP2:VP3 in a good stoichiometry resulting in AAV with high potency.Type: GrantFiled: January 15, 2020Date of Patent: June 6, 2023Assignee: uniQure IP B.V.Inventors: David Johannes Francois Du Plessis, Olivier Ter Brake, Sebastiaan Menno Bosma, Harald Peter Albert Petry, Jacek Lubelski
-
Patent number: 11649467Abstract: The invention provides adenoviral vectors comprising transgenes encoding Chikungunya virus antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Chikungunya virus infections.Type: GrantFiled: July 19, 2018Date of Patent: May 16, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Benjamin Wizel, Martine Harvey, Lucile Warter, Kate Luisi
-
Patent number: 11633468Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: August 17, 2020Date of Patent: April 25, 2023Assignee: Vactech OyInventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Patent number: 11623941Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, b) contacting a liquid sample comprising an immunoglobulin with the separation matrix, c) washing said separation matrix with a washing liquid, d) eluting the immunoglobulin from the separation matrix with an elution liquid, and e) cleaning the separation matrix with a cleaning liquid, wherein the alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 51 or SEQ ID NO: 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO: 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO: 51 or 52 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucType: GrantFiled: May 27, 2020Date of Patent: April 11, 2023Assignee: CYTIVA BIOPROCESS R&D ABInventors: Annika Kristina Forss, Gustav Jose Rodrigo, Tomas Bjorkman, Jesper Ulf Hansson, Mats Ander
-
Patent number: 11612337Abstract: The present invention includes a system and device for aiding in the diagnosis of a physiological abnormality resulting in detectable, measurable variations in contents of breathed air. The system includes a handheld unit defining an airway, wherein the airway includes a plurality of sensors adapted to measure a plurality of parameters related to the presence of a physiological abnormality. The system further includes a control unit remotely connected to the handheld unit. The control unit includes a controller adapted to receive input signals from the handheld unit and remit output signals in response thereto. The output signals are usable by a user in determining the presence or absence of a physiological abnormality. The control unit further also can include a display adapted to display the output signals to a user thereby easing the determination of the physiological abnormality. The system further includes a mouthpiece selectively connectable to the handheld unit.Type: GrantFiled: October 7, 2019Date of Patent: March 28, 2023Assignee: DEKA Products Limited PartnershipInventors: Derek G. Kane, Gregory R. Lanier, Jr., Eric Soderberg, Benjamin W. Jones, Jr., Paul Marquis
-
Patent number: 11596686Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: GrantFiled: August 9, 2022Date of Patent: March 7, 2023Assignee: CureVac SEInventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
-
Patent number: 11591364Abstract: Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.Type: GrantFiled: November 30, 2018Date of Patent: February 28, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ahmad Taimour Baig, Felicie Georgette Colette Denet, Juan Jose Diaz Garcia, Chad Austin Farrenburg, Lora Lea Lawrence, Kent Raymond Myers, Jeri Kay Sandvick, Jeb Yeatts Vandenburg
-
Patent number: 11576966Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: GrantFiled: November 15, 2021Date of Patent: February 14, 2023Assignee: CureVac SEInventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
-
Patent number: 11572390Abstract: Chimeric proteins that comprise one or more amino acid sequences of an insect-specific flavivirus and one or more other immunogenic proteins are provided. The chimeric proteins are suitably capable of forming virus particles. The chimeric protein and/or virus particle may be suitable for delivery to a subject to elicit an immune response to a pathogen and/or for diagnosis or detection of a pathogen. Also provided are nucleic acids and vectors encoding the chimeric proteins, and isolated chimeric insect-specific flaviviruses comprising the chimeric proteins and/or nucleic acids.Type: GrantFiled: September 7, 2017Date of Patent: February 7, 2023Assignee: THE UNIVERSITY OF QUEENSLANDInventors: Roy Hall, Jody Hobson-Peters, Alexander Khromykh, Daniel Watterson, Mn Setoh, Thisun Piyasena, Agathe Colmant, Jessica Harrison, N Ata Lee Newton, Laura Vet, Helle Bielefeldt-Ohmann
-
Patent number: 11564985Abstract: A fusion protein is provided which is based on a self-assembling gene-regulatory NSP10 protein and a protein or peptide capable of being fused to NSP10 without interfering with the assembly or aggregation of the resulting fusion protein. The disclosure also relates to any nanoparticle formed thereby whether complete or not, and methods for the use of the NSP10 fusion protein are also disclosed, including use as vaccines for any indication in humans or animals, therapeutic methods involving the use of the fusion proteins such as using the protein to targeted an antibody or receptor, such as for treating or diagnosing cancer, biosensors using the fusion protein, or the use of the fusion proteins in cell sorting or any imaging application.Type: GrantFiled: June 23, 2020Date of Patent: January 31, 2023Inventor: Daniel C. Carter
-
Patent number: 11564983Abstract: The present invention relates to the production of the receptor binding domain (RBD) of the Spike glycoprotein 1 of the SARS-CoV-2 in mammalian cell expression systems, and the successive method of purification thereof. A recombinant plasmid containing the coding sequence of said RBD is produced and transfected in said mammalian cells, for example, Expi293. A high level of the protein is secreted in the medium and subsequently purified using the N-terminal tag, that can be removed by a specific protease. The present invention also includes a recombinant expression vector carrying the RBD gene, the successive methods for protein purification, the strategy for establishing a stable cell line producing the RBD, methods of use of the recombinant protein in formulating a pharmaceutical composition, including but not limited to, vaccines for preventing SARS-CoV-2 induced diseases.Type: GrantFiled: January 25, 2022Date of Patent: January 31, 2023Assignee: Betagen Scientific LimitedInventors: Alan Chang, Fabrizio Maria Anella, Clement M. Lee, Bing Lou Wong
-
Patent number: 11542527Abstract: The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide.Type: GrantFiled: August 10, 2020Date of Patent: January 3, 2023Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventor: Biao He
-
Patent number: 11541113Abstract: The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: GrantFiled: December 10, 2021Date of Patent: January 3, 2023Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Shinu John
-
Patent number: 11510977Abstract: Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.Type: GrantFiled: January 31, 2022Date of Patent: November 29, 2022Assignee: Suzhou Abogen Biosciences Co., Ltd.Inventor: Bo Ying
-
Patent number: 11512327Abstract: The invention provides compositions and methods for the preparation, manufacture, formulation and therapeutic use of adeno-associated virus (AAV) particles for the prevention and/or treatment of diseases.Type: GrantFiled: August 3, 2018Date of Patent: November 29, 2022Assignee: Voyager Therapeutics, Inc.Inventors: Dinah Wen-Yee Sah, Holger Patzke, Jinzhao Hou, Mathieu E. Nonnenmacher, Martin Goulet, Todd Carter
-
Patent number: 11510973Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.Type: GrantFiled: March 11, 2022Date of Patent: November 29, 2022Assignee: GRITSTONE BIO, INC.Inventors: Wade Blair, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin
-
Patent number: 11504421Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.Type: GrantFiled: May 8, 2018Date of Patent: November 22, 2022Assignee: GRITSTONE BIO, INC.Inventors: Wade Blair, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin
-
Patent number: 11484586Abstract: The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.Type: GrantFiled: June 13, 2018Date of Patent: November 1, 2022Assignees: Thomas Jefferson University, ICAHN School of Medicine at Mount SinaiInventors: Matthias Schnell, Christine Rettew Fisher, Christoph Wirblich, Gene Tan
-
Patent number: 11434261Abstract: The present invention is directed to the expression and secretion the Zika virus envelope protein. Elements of the pre-membrane and envelope sequence have been modified to enhance the expression of the envelope protein as a secreted product in the culture medium of transformed insect cell lines. The expressed and purified product is suitable as a vaccine antigen.Type: GrantFiled: July 26, 2017Date of Patent: September 6, 2022Assignee: Hawaii Biotech Inc.Inventor: David E. Clements
-
Patent number: 11435351Abstract: Compositions and methods for determining the efficacy and/or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and frozen. Upon thawing aliquots these cells are activated by exposure to a series of dilutions of q vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and/or potency.Type: GrantFiled: April 17, 2019Date of Patent: September 6, 2022Assignee: BioMadison, Inc.Inventor: Ward C Tucker